Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
The FDA asked, and Eli Lilly and Company delivered. The company now hopes to secure an additional approval for orforglipron/Foundayo that covers the treatment of type 2 diabetes.
Of all lawsuits filed against patients in 2024 in one U.S. state, physician practices and other non-hospital healthcare entities accounted for 80% of cases. That’s a complete inversion from just six years prior.
In the three or so years since it burst into healthcare, ambient AI scribe technology has run away with the win in the market-uptake race. What has been the return on investment in all those software packages?
Stacy Sanso—director of patient access for ARA Diagnostic Imaging, the Austin, Texas, affiliate of Radiology Partners—takes over as president of the association.
Complaints stemming from such delays prompted officials to look further into the issue, eventually leading them to discover that nearly 200 reports had not been sent to patients’ referring providers.
High consumption of these foods could lead to increased levels of intramuscular fat—a known marker of poor muscle health, according to new research published in Radiology.
Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
